Marjeta Urh
Marjeta Urh publishes mostly in Molecular Biology, Radiology, Nuclear Medicine and Imaging and Oncology, on topics such as Protein Degradation and Inhibitors, Monoclonal and Polyclonal Antibodies Research and Ubiquitin and proteasome pathways.
- World rank
- #637,684 of 7,710,434 ranked researchers
- Rank in United States
- #217,565 of 1,627,098
- Works
- 108
- Citations
- 6.3k
- Citations per work
- 58.8
What does Marjeta Urh research?
Marjeta Urh's work is mostly in Biochemistry, Genetics and Molecular Biology (54%), Medicine (22%), Chemistry (6%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Life Sciences5854.1%
- Health Sciences2321.5%
- Medicine2321.5%
- Everything else2018.2%
- Physical Sciences76.2%
- Chemistry76.2%
- 1Molecular Biology50% of their works
- 2Radiology, Nuclear Medicine and Imaging9% of their works
- 3Oncology8% of their works
- 4Spectroscopy6% of their works
- 5Hematology4% of their works
- 6Genetics4% of their works
Research topics
- Protein Degradation and Inhibitors
- Monoclonal and Polyclonal Antibodies Research
- Ubiquitin and proteasome pathways
- Advanced Biosensing Techniques and Applications
- Protein purification and stability
- Multiple Myeloma Research and Treatments
- Peptidase Inhibition and Analysis
- Advanced Proteomics Techniques and Applications
Which keywords describe Marjeta Urh's research?
The keywords of their largest research topics: Monoclonal Antibodies, Therapeutic Antibodies, Cancer Therapy, Proteasome Inhibitors, BET Bromodomains, PROTACs, Antibody Engineering and Fc Receptors.
- Proteomics
- Tumor Microenvironment
- Fibroblast Activation Protein
- Protein Aggregation
- Protein Microarrays
- Ubiquitin
- Fc Receptors
- PROTACs
- Proteasome Inhibitors
- Therapeutic Antibodies
- Monoclonal Antibodies
- Cancer Therapy
- BET Bromodomains
- Antibody Engineering
- Proteasome
- High-Throughput Analysis
- Biopharmaceuticals
- Diagnosis Criteria
- International Myeloma Working Group
- Mass Spectrometry
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most.
All 20 words, with their numbers
- Monoclonal Antibodies362 topics
- Therapeutic Antibodies362 topics
- Cancer Therapy312 topics
- Proteasome Inhibitors312 topics
- BET Bromodomains301 topic
- PROTACs301 topic
- Antibody Engineering241 topic
- Fc Receptors241 topic
- Proteasome201 topic
- Ubiquitin201 topic
- High-Throughput Analysis161 topic
- Protein Microarrays161 topic
- Biopharmaceuticals121 topic
- Protein Aggregation121 topic
- Diagnosis Criteria111 topic
- Fibroblast Activation Protein111 topic
- International Myeloma Working Group111 topic
- Tumor Microenvironment111 topic
- Mass Spectrometry101 topic
- Proteomics101 topic
Where does Marjeta Urh work?
Marjeta Urh's main affiliation in the publication record is Promega (United States), United States.
How many publications and citations does Marjeta Urh have?
OpenAlex counts 108 works and 6,346 citations for Marjeta Urh, an h-index of 30, ranking #637,684 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Marjeta Urh. Posts are plain text and can be reported.